Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan.
Am J Otolaryngol. 2011 Nov-Dec;32(6):624-6. doi: 10.1016/j.amjoto.2010.11.014. Epub 2011 Feb 15.
We report the rare case of angioedema (also known as Quincke edema), which was induced by valsartan, an angiotensin II receptor blocker (ARB). ARBs are a new class of antihypertensive agent that is developed to exclude the adverse effects of angiotensin-converting enzyme inhibitors. In theory, ARBs do not contribute to the occurrence of angioedema because they do not increase the serum level of bradykinin, the responsible substance for angioedema. However, some reports of ARB-induced angioedema have recently been published. In this study, we present the forth case and the first Asian case of angioedema due to valsartan, which is one of the ARBs. Otolaryngologist should be wary of the prescribing ARB and discontinue ARBs treatment soon, if angioedema is recognized.
我们报告了一例血管性水肿(也称为 Quincke 水肿)的罕见病例,该病例由血管紧张素 II 受体阻滞剂(ARB)缬沙坦引起。ARB 是一类新型的降压药,旨在排除血管紧张素转换酶抑制剂的不良反应。理论上,ARB 不会导致血管性水肿的发生,因为它们不会增加血管性水肿的责任物质缓激肽的血清水平。然而,最近已经发表了一些关于 ARB 引起的血管性水肿的报告。在本研究中,我们报告了第四例也是首例亚洲人因血管紧张素 II 受体阻滞剂缬沙坦引起的血管性水肿病例。耳鼻喉科医生应警惕 ARB 的处方,并在识别出血管性水肿时尽快停止 ARB 治疗。